Amitriptyline

證據等級: L5

預測適應症: 10 個

Amitriptyline: From Major Depressive Disorder to Multiple Psychiatric Indications

One-Sentence Summary

Amitriptyline is a first-generation tricyclic antidepressant (TCA) used clinically since 1961, with its core mechanism centered on dual inhibition of norepinephrine (NE) and serotonin (5-HT) reuptake, alongside significant antihistaminic and anticholinergic properties. The TxGNN model generates 10 predictions across psychiatric and neurological conditions, led by benign paroxysmal torticollis of infancy (highest TxGNN score: 97.72%, but L5/Hold) and including major depressive disorder (rank #4, 96.85%, L1 — the strongest clinical evidence tier, supported by a landmark 522-RCT network meta-analysis covering 116,477 patients and multiple completed Phase 3 trials). The overall prediction cluster aligns closely with amitriptyline's established pharmacology — dominated by depression subtypes and anxiety-related conditions — though two predictions (Ohdo syndrome variants) are assessed as likely knowledge-graph false positives with no mechanistic basis.

Quick Overview

Item	Content
Original Indication	Major depressive disorder (established TCA antidepressant since 1961; no Singapore HSA registrations found)
Top TxGNN Prediction (by score)	Benign paroxysmal torticollis of infancy
TxGNN Prediction Score	97.72%
Best-Evidenced Prediction	Major depressive disorder (rank #4)
Evidence Level (Best)	L1
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	See Multi-Indication Summary below

Multi-Indication Prediction Summary

Rank	Indication	TxGNN Score	Evidence Level	Decision
1	Benign paroxysmal torticollis of infancy	97.72%	L5	Hold
2	Endogenous depression	97.71%	L2	Proceed with Guardrails
3	Agoraphobia	97.27%	L4	Research Question
4	Major depressive disorder	96.85%	L1	Proceed with Guardrails
5	Ohdo syndrome and variants	95.95%	L5	Hold
6	Melancholia	95.52%	L2	Proceed with Guardrails
7	Neurotic depression	95.48%	L2	Proceed with Guardrails
8	Phobic disorder	94.68%	L4	Research Question
9	Unipolar depression	94.61%	L1	Proceed with Guardrails
10	Blepharophimosis-intellectual disability syndrome, Ohdo type	94.47%	L5	Hold

Why is This Prediction Reasonable?

Although detailed MOA data was not retrieved in this Evidence Pack, amitriptyline's pharmacology is among the best-documented in modern psychiatry (see PMID 33438398, ACS Chemical Neuroscience, 2021). Amitriptyline inhibits the presynaptic reuptake of both norepinephrine and serotonin by blocking the NET and SERT transporters, directly addressing the monoamine deficiency hypothesis of depression. Beyond this primary mechanism, it exhibits potent antagonism at H1 histamine receptors (contributing to sedation and appetite stimulation), muscarinic acetylcholine receptors (explaining anticholinergic side effects), and α1-adrenergic receptors (producing anxiolytic effects through dampening of sympathetic output).

The TxGNN prediction cluster of five depression subtypes — major depressive disorder, endogenous depression, melancholia, neurotic depression, and unipolar depression — is entirely consistent with this dual-reuptake inhibition core mechanism. The variation in evidence levels across these subtypes reflects diagnostic nomenclature evolution rather than genuine mechanistic differences: "endogenous depression" and "neurotic depression" are DSM-III-era terms now subsumed within DSM-5 MDD specifiers (melancholic features, anxious distress). Older RCTs from the 1980s–1990s using these labels provide direct evidence, though modern trials no longer employ this terminology. The anxiety-related predictions (agoraphobia rank #3, phobic disorder rank #8) are pharmacologically plausible: α1-adrenergic blockade reduces autonomic symptoms of anxiety, and 5-HT modulation is central to panic-spectrum disorder treatment. The imipramine TCA has established RCT evidence for panic disorder, supporting a class-effect inference for amitriptyline.

The rank #1 prediction — benign paroxysmal torticollis of infancy (BPTI) — is the most speculative. BPTI is classified as a childhood migraine equivalent with CACNA1A calcium channel associations, and amitriptyline is used off-label for migraine prophylaxis through Na⁺ channel modulation and 5-HT modulation. The TxGNN knowledge graph likely detected an indirect linkage through shared migraine-BPTI graph nodes. However, no clinical evidence exists, and the infant patient population raises serious safety concerns for a TCA. The Ohdo syndrome predictions (ranks #5 and #10) represent structural genetic developmental disorders caused by MED13L, KAT6A, or SETD5 mutations — none of which are connected to monoamine pharmacology — and are assessed as false-positive predictions arising from non-specific neuronal plasticity node associations in the knowledge graph.

Clinical Trial Evidence

Trials retrieved for Major Depressive Disorder (rank #4, L1 — highest clinical evidence among all 10 predictions). No clinical trials were identified for ranks #1–3 or #5–10.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05952713	N/A	Completed	73,336	Nationwide real-world study comparing 15 antidepressants (including amitriptyline) in MDD patients, emulating a randomized trial with high external validity
NCT00351910	Phase 3	Completed	494	Double-blind, placebo-controlled RCT: quetiapine fumarate SR added to antidepressant (including amitriptyline) vs antidepressant alone in MDD with inadequate response
NCT04777006	Phase 4	Active, Not Recruiting	487	Stepped-care model integrating depression screening and treatment (amitriptyline as first-line) into Malawi's national HIV care delivery platform
NCT01049347	Phase 3	Completed	127	Longitudinal study of HPA axis mineralocorticoid receptor function during amitriptyline and paroxetine treatment in moderately-to-severely depressed patients
NCT02014363	Phase 2	Completed	164	Non-inferiority study: ETS6103 vs amitriptyline in SSRI-resistant MDD patients; validates amitriptyline as the benchmark active comparator
NCT05931965	N/A	Completed	88	Antidepressants in combination with L-methylfolate, Vitamin B12, or magnesium in depressive disorders; PHQ-9 as primary outcome
NCT02237937	Phase 4	Unknown	80	ABCB1 genotype-guided dose escalation strategy for P-glycoprotein substrate antidepressants including amitriptyline; pharmacogenomics approach to MDD
NCT00704860	Phase 4	Completed	27	Treatment-resistant depression, hippocampal atrophy, and serotonin genetic polymorphism; antidepressants may protect against hippocampal volume loss

Literature Evidence

Top 10 publications for Major Depressive Disorder (rank #4), prioritised by study quality (Tier 1 > Tier 2 > Tier 3):

PMID	Year	Type	Journal	Key Findings
23235671	2012	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Amitriptyline vs placebo for MDD: meta-analysis confirming significant superiority; establishes amitriptyline as the "benchmark" antidepressant for comparative trials
29477251	2018	Network Meta-Analysis	The Lancet	21 antidepressants, 522 RCTs, 116,477 patients: amitriptyline efficacy OR 2.13 vs placebo; ranked superior to 13 of 20 comparator drugs in acute MDD treatment
36253442	2023	Network Meta-Analysis	Molecular Psychiatry	Maintenance-phase antidepressant NMA using double-blind placebo-controlled trials with enrichment design; supports long-term efficacy of amitriptyline in MDD relapse prevention
38360024	2024	Network Meta-Analysis	The Lancet Psychiatry	Pharmacological treatments for psychotic depression: NMA comparing amitriptyline-antipsychotic combinations vs alternatives; informs combination therapy decisions
27289172	2016	Network Meta-Analysis	The Lancet	Antidepressants in children and adolescents with MDD: amitriptyline included; important note that efficacy-to-tolerability ratio may be less favourable in this population
38856993	2024	Narrative Review	JAMA	Management of Depression in Adults (JAMA 2024): contemporary clinical practice guidance; amitriptyline cited as an established treatment option with well-characterised risk profile
38379028	2024	Cohort Study	Acta Psychiatrica Scandinavica	2-year nationwide comparative responses to 17 antidepressants in MDD, emulating a randomised trial; real-world long-term effectiveness data for amitriptyline
25911132	2015	Evidence-Based Review	Journal of Affective Disorders	Dose equivalents of antidepressants derived from RCT data; provides systematic, evidence-based dosing benchmarks for amitriptyline vs other agents
28850959	2018	Systematic Review	Pharmacopsychiatry	Epileptic seizures under antidepressant treatment: amitriptyline associated with higher seizure risk compared to SSRIs — clinically important safety consideration
33438398	2021	Review	ACS Chemical Neuroscience	Classics in Chemical Neuroscience: Amitriptyline — comprehensive review of mechanism (NE/5-HT reuptake inhibition, off-target receptor profile), clinical history, and cardiotoxicity profile

Safety Considerations

Formal Singapore HSA warning labels and contraindications data were not available in this Evidence Pack (Data Gap DG001, classified as Blocking severity). The following key safety information is drawn from the clinical literature:

Cardiac toxicity: Amitriptyline prolongs the QT interval and can cause atrioventricular conduction disturbances, particularly dangerous in overdose settings — a critical concern when prescribing to patients with active suicidal ideation.
Anticholinergic effects: Dry mouth, urinary retention, constipation, blurred vision, and cognitive impairment are common; risk is significantly amplified in elderly patients and those on other anticholinergic agents.
Seizure threshold lowering: The TCA class is associated with dose-dependent reduction in seizure threshold (PMID 28850959); use with caution in patients with epilepsy history.
Overdose risk: TCAs have a narrow therapeutic window; amitriptyline is among the most lethal antidepressants in overdose due to cardiac toxicity — prescribing should be limited to trusted settings with quantity dispensing controls.
Manic switch risk: TCA monotherapy in patients with undiagnosed bipolar disorder can precipitate manic or hypomanic episodes; bipolar disorder must be screened for before initiation.

Conclusion and Next Steps

Priority 1 — Major Depressive Disorder and Unipolar Depression

Decision: Proceed with Guardrails

Rationale: The Cochrane systematic review (PMID 23235671), the 2018 Lancet network meta-analysis (PMID 29477251, 522 RCTs, 116,477 patients), and multiple completed Phase 3 trials collectively establish L1-level evidence for amitriptyline in MDD and unipolar depression. With zero Singapore HSA registrations despite global approval and decades of evidence, this represents a clear regulatory opportunity — particularly valuable as an affordable treatment option.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain Singapore HSA package insert or product information for warnings, contraindications, and prescribing information
Prepare HSA registration submission supported by Cochrane SR and Lancet NMA as pivotal evidence
Develop risk management plan: cardiac monitoring protocol, quantity-per-prescription limits to reduce overdose risk, anticholinergic risk stratification for elderly patients
Define amitriptyline's positioning relative to SSRIs/SNRIs (TCA typically second-line; melancholic subtype may be first-line)
Require mandatory bipolar disorder screening before initiation

Priority 2 — Endogenous Depression, Melancholia, Neurotic Depression

Decision: Proceed with Guardrails

Rationale: These DSM-III-era subtypes carry direct 1980s–1990s RCT evidence with amitriptyline as the study drug (e.g., PMID 6452798, PMID 10757255, PMID 7049292). They map directly onto DSM-5 MDD specifiers (melancholic features, anxious distress), meaning the existing L1 MDD evidence base is applicable. The L2 classification reflects diagnostic nomenclature obsolescence, not evidence weakness.

To proceed:

Leverage existing MDD registration filing; melancholic and endogenous subtype RCTs support expanded labelling claims
No separate registration pathway needed; document as subpopulation evidence in clinical overview

Priority 3 — Agoraphobia and Phobic Disorder

Decision: Research Question

Rationale: TCA class-effect evidence (imipramine for panic disorder, clomipramine for OCD/agoraphobia) provides mechanistic plausibility, but direct amitriptyline RCTs for these indications are absent. L4 evidence level is insufficient for regulatory pursuit without further clinical investigation.